Description
CNS is one of the largest and fastest growing therapeutic areas of the pharmaceutical market. The ageing of the baby-boom generation combined with new and emerging treatments for neurodegenerative disorders, including multiple sclerosis, Alzheimer`s disease and Parkinson`s disease, will lead to further expansion of the neurodegenerative therapies market.
By attending this conference you will:
Examine novel approaches for assessing cognitive function
Explore the latest advances in neuroimaging
Develop effective methods for improved patient recruitment and retention
Understand statistical thinking for designing adaptive trials
Review Good Clinical Practice GCP guidelines
Address the regulatory challenges for CNS drug approval
Utilise biomarkers for Proof of Concept in CNS clinical trials
Improve trial outcomes through increased communication, ethical consent and patient care
Implement translational methods to bridge the gap between pre-clinical and clinical CNS trials
Be part of a major networking opportunity
